Atossa Therapeutics, Inc.’s Post

Join us tomorrow, Sunday, June 2, during the ASCO Annual Meeting for a groundbreaking poster presentation between 9:00 a.m. to 12:00 p.m. Our recent study utilizing the ConcertAI Oncology Dataset has revealed promising results for patients with metastatic castration-resistant prostate cancer. Through a collaboration with Merck and AstraZeneca our real-world analysis has demonstrated that early treatment with Olaparib monotherapy could potentially enhance the duration of therapy and overall survival rates for these patients. This study underscores the importance of leveraging data to make informed treatment decisions that can ultimately improve patient outcomes. Read abstract: https://hubs.ly/Q02z9qws0 #ASCO24 #OncologyResearch #RealWorldData #OlaparibMonotherapy #PatientCare

The FDA has approved durvalumab (Imfinzi) for limited-stage small cell lung cancer, a significant step forward for oncology care. At CSI, we understand the urgency of sourcing breakthrough comparators into clinical trials. If your study requires Imfinzi, our team can efficiently source it to keep your trials moving forward. With expertise in global studies and a commitment to reducing lead times, we’re here to support your trial success. #OncologyComparators #ClinicalTrials #Imfinzi #FullSupplyChainSolutions

We are sharing #FastFacts for #OvarianCancerAwarenessMonth. A subset of our ovarian cancer population showed that 70% had the subtype of serous ovarian carcinoma. We understand the vital role that data plays in precision oncology. Learn how our real-world data and expertise can support innovation for drug development: https://lnkd.in/gHc2NcSQ #RealWorldData #RWD #OvarianCancer #ovariancarcinoma

BIO-ACADEMIA: In a stride towards enhancing HER2-positive breast cancer treatment, Korean scientists at Korea University have introduced HVH-2930, an HSP90 inhibitor poised to redefine therapeutic outcomes. Click to read: https://lnkd.in/gAx3Sebz #academia #therapeutic #breastcancer #cancertreatment #inhibitor #biovoicenews

Another important publication demonstrating Fortrea's leadership across oncology clinical development. Breast cancer is a leading cause of mortality and morbidity worldwide. This article reviews the current landscape of neoadjuvant therapy for HR+/HER2- breast cancer, focusing on #biomarkers for decision making, and exploring next steps of #clinicalresearch in this therapeutic space. #oncologyclinicaltrials

Watch: Our CMO <Garrett Nichols, MD, MS, discusses Candel's phase 3 trial investigating CAN-2409 in intermediate to high-risk localized prostate cancer. With 711 patients enrolled, this study could represent the first significant advancement in localized prostate cancer treatment in decades. https://lnkd.in/euDWhE2u #ClinicalTrials #ProstateCancer #BiotechInnovation 

Developing effective, human-specific cancer therapies starts with selecting the right research models that are best suited to evaluate them. If you’re looking to optimize your #oncology research and make it more translatable, join our webinar for a look at different models of humanization highlighting various oncology applications. https://okt.to/2KHq4e

📚💡❗ARV-471 Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer

My first publication β-Arrestin inhibition induces autophagy, apoptosis, G0/G1 cell cycle arrest in agonist-activated V2R receptor in breast cancer cells https://lnkd.in/dxT2pkEK

Dive into the world of antibody-drug conjugates with Sino Biological, Inc.! Discover how these innovative therapeutics target cancer cells with precision, sparing healthy tissues from harm. Read their latest article to learn more about the latest advancements in cancer treatment! >>> https://hubs.ly/Q02qHYlG0